Acro Biomedical Co., Ltd.
ACBM
$0.0007
-$0.1043-99.33%
OTC PK
| 03/31/2025 | 09/30/2024 | 03/31/2024 | 12/31/2023 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -13.59% | -99.23% | -99.31% | -98.82% | -98.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.59% | -99.42% | -99.74% | -99.59% | -99.59% |
| Operating Income | 13.59% | 99.42% | 99.74% | 99.56% | 99.56% |
| Income Before Tax | 8.85% | 99.36% | 99.72% | 99.54% | 99.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.85% | 99.36% | 99.72% | 99.54% | 99.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.85% | 99.36% | 99.72% | 99.54% | 99.54% |
| EBIT | 13.59% | 99.42% | 99.74% | 99.56% | 99.56% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00% | 99.25% | 99.70% | 99.54% | 99.54% |
| Normalized Basic EPS | 0.00% | 99.39% | 99.76% | 99.51% | 99.51% |
| EPS Diluted | 0.00% | 99.25% | 99.70% | 99.54% | 99.54% |
| Normalized Diluted EPS | 0.00% | 99.39% | 99.76% | 99.51% | 99.51% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |